Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation
NCT04792658 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-03-11
Summary
Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction.
previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.
Conditions
- Psychiatric Disorder
- Benzodiazepine-Related Disorders
Interventions
- BEHAVIORAL
-
Detailed interview with personal demographic data
, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
- BEHAVIORAL
-
Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)
the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
- BEHAVIORAL
-
The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)
it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
- BEHAVIORAL
-
the Hamilton Depression Rating Scale
it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
- BEHAVIORAL
-
The Hamilton Anxiety Rating Scale
it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
- BEHAVIORAL
-
The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)
It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-10
- Primary Completion
- 2022-06-20
- Completion
- 2023-09-20
More Related Trials
-
Use of Benzodiazepines and Z Drugs in the Elderly
NCT01920581 ·Status: UNKNOWN
-
Exploring the Effects of Diazepam and Lorazepam
NCT00696033 ·Status: COMPLETED ·Phase: NA
-
Prevention of Benzodiazepine Misuse in Primary Care
NCT04533230 ·Status: WITHDRAWN ·Phase: NA
-
Psychopharmacological Treatment of Emotional Distress
NCT06133114 ·Status: RECRUITING ·Phase: PHASE4
-
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
NCT06446349 ·Status: RECRUITING ·Phase: NA
-
TREC-Lebanon: A Trial for Rapid Tranquilisation for Agitated Patients in the Emergency Setting
NCT03639558 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
NCT00902772 ·Status: COMPLETED ·Phase: PHASE1
-
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
NCT00681746 ·Status: COMPLETED ·Phase: PHASE1
-
Rapid Benzodiazepine Detoxification Using Flumazenil - 1
NCT00000246 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
NCT03090620 ·Status: COMPLETED ·Phase: PHASE4
-
Clonidine vs. Dexmedetomidine in Agitated Delirium in Intensive Care Patients
NCT04758936 ·Status: UNKNOWN ·Phase: PHASE4
-
Acute Agitation in Emergency Psychiatry
NCT06752616 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
NCT03110900 ·Status: TERMINATED ·Phase: PHASE4
-
GABA Pathways in Autism Spectrum Disorder (ASD)
NCT03678129 ·Status: COMPLETED ·Phase: NA
-
Multimodal Educative Data Feedback for Deprescribing BZD and Related Drugs in Outpatients: a Cluster RCT
NCT05859555 ·Status: COMPLETED ·Phase: NA
-
Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction
NCT03065998 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Propranolol Versus Propranolol and Clonidine in Sympathetic Hyperactivity After Moderate Traumatic Brain Injury
NCT04833218 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
NCT03286218 ·Status: COMPLETED ·Phase: PHASE1
-
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room
NCT00457366 ·Status: COMPLETED ·Phase: PHASE4
-
Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325
NCT00681720 ·Status: COMPLETED ·Phase: PHASE1
-
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
NCT04970342 ·Status: COMPLETED ·Phase: PHASE1
-
Opiates and Benzodiazepines on Driving
NCT03447353 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865
NCT02138500 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of THC and CBD on Human Episodic Memory Function
NCT02291562 ·Status: COMPLETED ·Phase: NA
-
Spectroscopic Imaging at 4T: A Drug Challenge Study
NCT01577706 ·Status: TERMINATED ·Phase: NA